Indications |
Nasal Treatment and prophylaxis of allergic rhinitis Adult: 100 mcg into each nostril once daily, increased to 100 mcg bid. Child: >4 yr: 50 mcg into each nostril once daily, increased to 50 mcg bid. Nasal Nasal polyps Adult: As propionate: 200 mcg to be instilled into each nostril 1-2 times daily for at least 4-6 wk. Inhalation Asthma prophylaxis Adult: As powder or aerosol: 100-250 mcg bid in mild cases, up to 500-1000 mcg bid in severe cases. Child: As powder or aerosol: >4 yr: Initially, 50-100 mcg bid. May increase to 200 mcg, if necessary. Inhalation Severe asthma Adult: As nebuliser: 0.5-2 mg bid. Child: As nebuliser: 4-16 yr: 1 mg bid. Inhalation Chronic obstructive pulmonary disease Adult: As powder or aerosol: 500 mcg bid. Topical/Cutaneous Corticosteroid-responsive dermatoses Adult: As propionate: Apply a 0.05 or 0.005% cream/ointment onto affected area. |
Contraindications |
Hypersensitivity. Acne vulgaris, rosacea, perioral dermatitis, skin atrophy; hypersensitivity. Primary cutaneous viral infections (e.g. herpes simplex, chicken pox), perianal and genital pruritus, primary fungal or bacterial skin infections. Inhalation: Status asthmaticus. |
Warnings / Precautions |
Children, pregnancy, lactation, concomitant skin infections. Concomitant skin/lung/systemic infections. Advised to rinse mouth with water every time after inhalation. Application to large areas, broken skin or under occlusive dressings. |
Adverse Reactions |
Topical: Pruritus, hypertrichosis, dryness, numbness of fingers, burning, eruptions, hypopigmentation, allergic contact dermatitis, secondary infection, skin atrophy, Cushing's syndrome, reversible HPA-axis suppression. Inhalation: Oropharyngeal candidiasis, pharyngitis, dysphoria, cough, rhinitis, nasal congestion and headache. Systemic absorption may be seen when applied to large areas, when skin is broken or under occlusive dressings. Potentially Fatal: Suppression of immune system. |
Drug Interactions |
May lead to increased plasma concentrations of fluticasone when used with CYP4503A4 inhibitors such as ritonavir. See Below for More fluticasone Drug Interactions |
Mechanism of Actions |
Fluticasone utilises a fluorocarbothioate ester linkage at the C17 position. It has potent vasoconstrictive and anti-inflammatory activity, but weak HPA inhibitory effect when applied topically. Absorption: Poorly absorbed from the GI tract (oral). Distribution: Protein-binding: 91%. Metabolism: Extensively hepatic; converted to 17β-carboxylic acid. Excretion: Faeces (as unchanged drug and metabolites), urine (as metabolites). |
Storage Conditions |
Inhalation: Store at 25°C. Nasal: Store at 4-30°C. Topical/Cutaneous: Store at 15-30 °C. |
ATC Classification |
D07AC17 - fluticasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases. R01AD08 - fluticasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis. R03BA05 - fluticasone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids. |
Storage |
Inhalation: Store at 25°C. Nasal: Store at 4-30°C. Topical/Cutaneous: Store at 15-30 °C. |
Available As |
|
Fluticasone
Post Review about Fluticasone Click here to cancel reply.
Fluticasone Containing Brands
Fluticasone is used in following diseases
Drug - Drug Interactions of Fluticasone
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.